Macular Degeneration (AMD) and Other Retinal Diseases Market - Global Outlook and Forecast 2022-2028

March 2022 | 61 pages | ID: M0BBA115FB22EN
Market Monitor Global

Abstracts

Macular degeneration (AMD) and other retinal diseases are mainly related to long-term and chronic light damage in macular area, choroidal vascular sclerosis, and aging of retinal pigment epithelial cells, often including Lucentis, Eylea, Avastin and other brands.

This report contains market size and forecasts of Macular Degeneration (AMD) and Other Retinal Diseases in Global, including the following market information:

Global Macular Degeneration (AMD) and Other Retinal Diseases Market Revenue, 2017-2022, 2023-2028, ($ millions)

Global top five companies in 2021 (%)

The global Macular Degeneration (AMD) and Other Retinal Diseases market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

Macular Degeneration Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Macular Degeneration (AMD) and Other Retinal Diseases include Regeneron Pharmaceuticals, Bayer HealthCare, Novartis, Roche, Kanghong Pharma, Merck, Allergan, Santen Pharmaceutical and GlaxoSmithKline Pharmaceuticals, etc. In 2021, the global top five players have a share approximately % in terms of revenue.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Macular Degeneration (AMD) and Other Retinal Diseases companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Macular Degeneration (AMD) and Other Retinal Diseases Market, by Type, 2017-2022, 2023-2028 ($ millions)

Global Macular Degeneration (AMD) and Other Retinal Diseases Market Segment Percentages, by Type, 2021 (%)

• Macular Degeneration
• Diabetic Macular Edema
• Diabetic Retinopathy(DR)
• Retinal Vein Occlusion
• Wet Age-Related Macular Degeneration (wAMD)
• Dry Age-Related Macular Degeneration (dAMD)
• Other

Global Macular Degeneration (AMD) and Other Retinal Diseases Market, by Application, 2017-2022, 2023-2028 ($ millions)

Global Macular Degeneration (AMD) and Other Retinal Diseases Market Segment Percentages, by Application, 2021 (%)

• Hospital
• Clinic
• Other

Global Macular Degeneration (AMD) and Other Retinal Diseases Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)

Global Macular Degeneration (AMD) and Other Retinal Diseases Market Segment Percentages, By Region and Country, 2021 (%)

• North America
• US
• Canada
• Mexico
• Europe
• Germany
• France
• U.K.
• Italy
• Russia
• Nordic Countries
• Benelux
• Rest of Europe
• Asia
• China
• Japan
• South Korea
• Southeast Asia
• India
• Rest of Asia
• South America
• Brazil
• Argentina
• Rest of South America
• Middle East & Africa
• Turkey
• Israel
• Saudi Arabia
• UAE
• Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Macular Degeneration (AMD) and Other Retinal Diseases revenues in global market, 2017-2022 (estimated), ($ millions)

Key companies Macular Degeneration (AMD) and Other Retinal Diseases revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

• Regeneron Pharmaceuticals
• Bayer HealthCare
• Novartis
• Roche
• Kanghong Pharma
• Merck
• Allergan
• Santen Pharmaceutical
• GlaxoSmithKline Pharmaceuticals
• Pfizer
• Acucela
• Valent Pharmaceuticals
• IVERIC

Contents

1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS

1.1 Macular Degeneration (AMD) and Other Retinal Diseases Market Definition
1.2 Market Segments
  1.2.1 Market by Type
  1.2.2 Market by Application
1.3 Global Macular Degeneration (AMD) and Other Retinal Diseases Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
  1.5.1 Research Methodology
  1.5.2 Research Process
  1.5.3 Base Year
  1.5.4 Report Assumptions & Caveats

2 GLOBAL MACULAR DEGENERATION (AMD) AND OTHER RETINAL DISEASES OVERALL MARKET SIZE

2.1 Global Macular Degeneration (AMD) and Other Retinal Diseases Market Size: 2021 VS 2028
2.2 Global Macular Degeneration (AMD) and Other Retinal Diseases Market Size, Prospects & Forecasts: 2017-2028
2.3 Key Market Trends, Opportunity, Drivers and Restraints
  2.3.1 Market Opportunities & Trends
  2.3.2 Market Drivers
  2.3.3 Market Restraints

3 COMPANY LANDSCAPE

3.1 Top Macular Degeneration (AMD) and Other Retinal Diseases Players in Global Market
3.2 Top Global Macular Degeneration (AMD) and Other Retinal Diseases Companies Ranked by Revenue
3.3 Global Macular Degeneration (AMD) and Other Retinal Diseases Revenue by Companies
3.4 Top 3 and Top 5 Macular Degeneration (AMD) and Other Retinal Diseases Companies in Global Market, by Revenue in 2021
3.5 Global Companies Macular Degeneration (AMD) and Other Retinal Diseases Product Type
3.6 Tier 1, Tier 2 and Tier 3 Macular Degeneration (AMD) and Other Retinal Diseases Players in Global Market
  3.6.1 List of Global Tier 1 Macular Degeneration (AMD) and Other Retinal Diseases Companies
  3.6.2 List of Global Tier 2 and Tier 3 Macular Degeneration (AMD) and Other Retinal Diseases Companies

4 MARKET SIGHTS BY PRODUCT

4.1 Overview
  4.1.1 by Type - Global Macular Degeneration (AMD) and Other Retinal Diseases Market Size Markets, 2021 & 2028
  4.1.2 Macular Degeneration
  4.1.3 Diabetic Macular Edema
  4.1.4 Diabetic Retinopathy(DR)
  4.1.5 Retinal Vein Occlusion
  4.1.6 Wet Age-Related Macular Degeneration (wAMD)
  4.1.7 Dry Age-Related Macular Degeneration (dAMD)
  4.1.8 Other
4.2 By Type - Global Macular Degeneration (AMD) and Other Retinal Diseases Revenue & Forecasts
  4.2.1 By Type - Global Macular Degeneration (AMD) and Other Retinal Diseases Revenue, 2017-2022
  4.2.2 By Type - Global Macular Degeneration (AMD) and Other Retinal Diseases Revenue, 2023-2028
  4.2.3 By Type - Global Macular Degeneration (AMD) and Other Retinal Diseases Revenue Market Share, 2017-2028

5 SIGHTS BY APPLICATION

5.1 Overview
  5.1.1 By Application - Global Macular Degeneration (AMD) and Other Retinal Diseases Market Size, 2021 & 2028
  5.1.2 Hospital
  5.1.3 Clinic
  5.1.4 Other
5.2 By Application - Global Macular Degeneration (AMD) and Other Retinal Diseases Revenue & Forecasts
  5.2.1 By Application - Global Macular Degeneration (AMD) and Other Retinal Diseases Revenue, 2017-2022
  5.2.2 By Application - Global Macular Degeneration (AMD) and Other Retinal Diseases Revenue, 2023-2028
  5.2.3 By Application - Global Macular Degeneration (AMD) and Other Retinal Diseases Revenue Market Share, 2017-2028

6 SIGHTS BY REGION

6.1 By Region - Global Macular Degeneration (AMD) and Other Retinal Diseases Market Size, 2021 & 2028
6.2 By Region - Global Macular Degeneration (AMD) and Other Retinal Diseases Revenue & Forecasts
  6.2.1 By Region - Global Macular Degeneration (AMD) and Other Retinal Diseases Revenue, 2017-2022
  6.2.2 By Region - Global Macular Degeneration (AMD) and Other Retinal Diseases Revenue, 2023-2028
  6.2.3 By Region - Global Macular Degeneration (AMD) and Other Retinal Diseases Revenue Market Share, 2017-2028
6.3 North America
  6.3.1 By Country - North America Macular Degeneration (AMD) and Other Retinal Diseases Revenue, 2017-2028
  6.3.2 US Macular Degeneration (AMD) and Other Retinal Diseases Market Size, 2017-2028
  6.3.3 Canada Macular Degeneration (AMD) and Other Retinal Diseases Market Size, 2017-2028
  6.3.4 Mexico Macular Degeneration (AMD) and Other Retinal Diseases Market Size, 2017-2028
6.4 Europe
  6.4.1 By Country - Europe Macular Degeneration (AMD) and Other Retinal Diseases Revenue, 2017-2028
  6.4.2 Germany Macular Degeneration (AMD) and Other Retinal Diseases Market Size, 2017-2028
  6.4.3 France Macular Degeneration (AMD) and Other Retinal Diseases Market Size, 2017-2028
  6.4.4 U.K. Macular Degeneration (AMD) and Other Retinal Diseases Market Size, 2017-2028
  6.4.5 Italy Macular Degeneration (AMD) and Other Retinal Diseases Market Size, 2017-2028
  6.4.6 Russia Macular Degeneration (AMD) and Other Retinal Diseases Market Size, 2017-2028
  6.4.7 Nordic Countries Macular Degeneration (AMD) and Other Retinal Diseases Market Size, 2017-2028
  6.4.8 Benelux Macular Degeneration (AMD) and Other Retinal Diseases Market Size, 2017-2028
6.5 Asia
  6.5.1 By Region - Asia Macular Degeneration (AMD) and Other Retinal Diseases Revenue, 2017-2028
  6.5.2 China Macular Degeneration (AMD) and Other Retinal Diseases Market Size, 2017-2028
  6.5.3 Japan Macular Degeneration (AMD) and Other Retinal Diseases Market Size, 2017-2028
  6.5.4 South Korea Macular Degeneration (AMD) and Other Retinal Diseases Market Size, 2017-2028
  6.5.5 Southeast Asia Macular Degeneration (AMD) and Other Retinal Diseases Market Size, 2017-2028
  6.5.6 India Macular Degeneration (AMD) and Other Retinal Diseases Market Size, 2017-2028
6.6 South America
  6.6.1 By Country - South America Macular Degeneration (AMD) and Other Retinal Diseases Revenue, 2017-2028
  6.6.2 Brazil Macular Degeneration (AMD) and Other Retinal Diseases Market Size, 2017-2028
  6.6.3 Argentina Macular Degeneration (AMD) and Other Retinal Diseases Market Size, 2017-2028
6.7 Middle East & Africa
  6.7.1 By Country - Middle East & Africa Macular Degeneration (AMD) and Other Retinal Diseases Revenue, 2017-2028
  6.7.2 Turkey Macular Degeneration (AMD) and Other Retinal Diseases Market Size, 2017-2028
  6.7.3 Israel Macular Degeneration (AMD) and Other Retinal Diseases Market Size, 2017-2028
  6.7.4 Saudi Arabia Macular Degeneration (AMD) and Other Retinal Diseases Market Size, 2017-2028
  6.7.5 UAE Macular Degeneration (AMD) and Other Retinal Diseases Market Size, 2017-2028

7 PLAYERS PROFILES

7.1 Regeneron Pharmaceuticals
  7.1.1 Regeneron Pharmaceuticals Corporate Summary
  7.1.2 Regeneron Pharmaceuticals Business Overview
  7.1.3 Regeneron Pharmaceuticals Macular Degeneration (AMD) and Other Retinal Diseases Major Product Offerings
  7.1.4 Regeneron Pharmaceuticals Macular Degeneration (AMD) and Other Retinal Diseases Revenue in Global Market (2017-2022)
  7.1.5 Regeneron Pharmaceuticals Key News
7.2 Bayer HealthCare
  7.2.1 Bayer HealthCare Corporate Summary
  7.2.2 Bayer HealthCare Business Overview
  7.2.3 Bayer HealthCare Macular Degeneration (AMD) and Other Retinal Diseases Major Product Offerings
  7.2.4 Bayer HealthCare Macular Degeneration (AMD) and Other Retinal Diseases Revenue in Global Market (2017-2022)
  7.2.5 Bayer HealthCare Key News
7.3 Novartis
  7.3.1 Novartis Corporate Summary
  7.3.2 Novartis Business Overview
  7.3.3 Novartis Macular Degeneration (AMD) and Other Retinal Diseases Major Product Offerings
  7.3.4 Novartis Macular Degeneration (AMD) and Other Retinal Diseases Revenue in Global Market (2017-2022)
  7.3.5 Novartis Key News
7.4 Roche
  7.4.1 Roche Corporate Summary
  7.4.2 Roche Business Overview
  7.4.3 Roche Macular Degeneration (AMD) and Other Retinal Diseases Major Product Offerings
  7.4.4 Roche Macular Degeneration (AMD) and Other Retinal Diseases Revenue in Global Market (2017-2022)
  7.4.5 Roche Key News
7.5 Kanghong Pharma
  7.5.1 Kanghong Pharma Corporate Summary
  7.5.2 Kanghong Pharma Business Overview
  7.5.3 Kanghong Pharma Macular Degeneration (AMD) and Other Retinal Diseases Major Product Offerings
  7.5.4 Kanghong Pharma Macular Degeneration (AMD) and Other Retinal Diseases Revenue in Global Market (2017-2022)
  7.5.5 Kanghong Pharma Key News
7.6 Merck
  7.6.1 Merck Corporate Summary
  7.6.2 Merck Business Overview
  7.6.3 Merck Macular Degeneration (AMD) and Other Retinal Diseases Major Product Offerings
  7.6.4 Merck Macular Degeneration (AMD) and Other Retinal Diseases Revenue in Global Market (2017-2022)
  7.6.5 Merck Key News
7.7 Allergan
  7.7.1 Allergan Corporate Summary
  7.7.2 Allergan Business Overview
  7.7.3 Allergan Macular Degeneration (AMD) and Other Retinal Diseases Major Product Offerings
  7.7.4 Allergan Macular Degeneration (AMD) and Other Retinal Diseases Revenue in Global Market (2017-2022)
  7.7.5 Allergan Key News
7.8 Santen Pharmaceutical
  7.8.1 Santen Pharmaceutical Corporate Summary
  7.8.2 Santen Pharmaceutical Business Overview
  7.8.3 Santen Pharmaceutical Macular Degeneration (AMD) and Other Retinal Diseases Major Product Offerings
  7.8.4 Santen Pharmaceutical Macular Degeneration (AMD) and Other Retinal Diseases Revenue in Global Market (2017-2022)
  7.8.5 Santen Pharmaceutical Key News
7.9 GlaxoSmithKline Pharmaceuticals
  7.9.1 GlaxoSmithKline Pharmaceuticals Corporate Summary
  7.9.2 GlaxoSmithKline Pharmaceuticals Business Overview
  7.9.3 GlaxoSmithKline Pharmaceuticals Macular Degeneration (AMD) and Other Retinal Diseases Major Product Offerings
  7.9.4 GlaxoSmithKline Pharmaceuticals Macular Degeneration (AMD) and Other Retinal Diseases Revenue in Global Market (2017-2022)
  7.9.5 GlaxoSmithKline Pharmaceuticals Key News
7.10 Pfizer
  7.10.1 Pfizer Corporate Summary
  7.10.2 Pfizer Business Overview
  7.10.3 Pfizer Macular Degeneration (AMD) and Other Retinal Diseases Major Product Offerings
  7.10.4 Pfizer Macular Degeneration (AMD) and Other Retinal Diseases Revenue in Global Market (2017-2022)
  7.10.5 Pfizer Key News
7.11 Acucela
  7.11.1 Acucela Corporate Summary
  7.11.2 Acucela Business Overview
  7.11.3 Acucela Macular Degeneration (AMD) and Other Retinal Diseases Major Product Offerings
  7.11.4 Acucela Macular Degeneration (AMD) and Other Retinal Diseases Revenue in Global Market (2017-2022)
  7.11.5 Acucela Key News
7.12 Valent Pharmaceuticals
  7.12.1 Valent Pharmaceuticals Corporate Summary
  7.12.2 Valent Pharmaceuticals Business Overview
  7.12.3 Valent Pharmaceuticals Macular Degeneration (AMD) and Other Retinal Diseases Major Product Offerings
  7.12.4 Valent Pharmaceuticals Macular Degeneration (AMD) and Other Retinal Diseases Revenue in Global Market (2017-2022)
  7.12.5 Valent Pharmaceuticals Key News
7.13 IVERIC
  7.13.1 IVERIC Corporate Summary
  7.13.2 IVERIC Business Overview
  7.13.3 IVERIC Macular Degeneration (AMD) and Other Retinal Diseases Major Product Offerings
  7.13.4 IVERIC Macular Degeneration (AMD) and Other Retinal Diseases Revenue in Global Market (2017-2022)
  7.13.5 IVERIC Key News

8 CONCLUSION

9 APPENDIX

9.1 Note
9.2 Examples of Clients
9.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. Macular Degeneration (AMD) and Other Retinal Diseases Market Opportunities & Trends in Global Market
Table 2. Macular Degeneration (AMD) and Other Retinal Diseases Market Drivers in Global Market
Table 3. Macular Degeneration (AMD) and Other Retinal Diseases Market Restraints in Global Market
Table 4. Key Players of Macular Degeneration (AMD) and Other Retinal Diseases in Global Market
Table 5. Top Macular Degeneration (AMD) and Other Retinal Diseases Players in Global Market, Ranking by Revenue (2021)
Table 6. Global Macular Degeneration (AMD) and Other Retinal Diseases Revenue by Companies, (US$, Mn), 2017-2022
Table 7. Global Macular Degeneration (AMD) and Other Retinal Diseases Revenue Share by Companies, 2017-2022
Table 8. Global Companies Macular Degeneration (AMD) and Other Retinal Diseases Product Type
Table 9. List of Global Tier 1 Macular Degeneration (AMD) and Other Retinal Diseases Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Macular Degeneration (AMD) and Other Retinal Diseases Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 11. By Type – Global Macular Degeneration (AMD) and Other Retinal Diseases Revenue, (US$, Mn), 2021 & 2028
Table 12. By Type - Macular Degeneration (AMD) and Other Retinal Diseases Revenue in Global (US$, Mn), 2017-2022
Table 13. By Type - Macular Degeneration (AMD) and Other Retinal Diseases Revenue in Global (US$, Mn), 2023-2028
Table 14. By Application – Global Macular Degeneration (AMD) and Other Retinal Diseases Revenue, (US$, Mn), 2021 & 2028
Table 15. By Application - Macular Degeneration (AMD) and Other Retinal Diseases Revenue in Global (US$, Mn), 2017-2022
Table 16. By Application - Macular Degeneration (AMD) and Other Retinal Diseases Revenue in Global (US$, Mn), 2023-2028
Table 17. By Region – Global Macular Degeneration (AMD) and Other Retinal Diseases Revenue, (US$, Mn), 2021 & 2028
Table 18. By Region - Global Macular Degeneration (AMD) and Other Retinal Diseases Revenue (US$, Mn), 2017-2022
Table 19. By Region - Global Macular Degeneration (AMD) and Other Retinal Diseases Revenue (US$, Mn), 2023-2028
Table 20. By Country - North America Macular Degeneration (AMD) and Other Retinal Diseases Revenue, (US$, Mn), 2017-2022
Table 21. By Country - North America Macular Degeneration (AMD) and Other Retinal Diseases Revenue, (US$, Mn), 2023-2028
Table 22. By Country - Europe Macular Degeneration (AMD) and Other Retinal Diseases Revenue, (US$, Mn), 2017-2022
Table 23. By Country - Europe Macular Degeneration (AMD) and Other Retinal Diseases Revenue, (US$, Mn), 2023-2028
Table 24. By Region - Asia Macular Degeneration (AMD) and Other Retinal Diseases Revenue, (US$, Mn), 2017-2022
Table 25. By Region - Asia Macular Degeneration (AMD) and Other Retinal Diseases Revenue, (US$, Mn), 2023-2028
Table 26. By Country - South America Macular Degeneration (AMD) and Other Retinal Diseases Revenue, (US$, Mn), 2017-2022
Table 27. By Country - South America Macular Degeneration (AMD) and Other Retinal Diseases Revenue, (US$, Mn), 2023-2028
Table 28. By Country - Middle East & Africa Macular Degeneration (AMD) and Other Retinal Diseases Revenue, (US$, Mn), 2017-2022
Table 29. By Country - Middle East & Africa Macular Degeneration (AMD) and Other Retinal Diseases Revenue, (US$, Mn), 2023-2028
Table 30. Regeneron Pharmaceuticals Corporate Summary
Table 31. Regeneron Pharmaceuticals Macular Degeneration (AMD) and Other Retinal Diseases Product Offerings
Table 32. Regeneron Pharmaceuticals Macular Degeneration (AMD) and Other Retinal Diseases Revenue (US$, Mn), (2017-2022)
Table 33. Bayer HealthCare Corporate Summary
Table 34. Bayer HealthCare Macular Degeneration (AMD) and Other Retinal Diseases Product Offerings
Table 35. Bayer HealthCare Macular Degeneration (AMD) and Other Retinal Diseases Revenue (US$, Mn), (2017-2022)
Table 36. Novartis Corporate Summary
Table 37. Novartis Macular Degeneration (AMD) and Other Retinal Diseases Product Offerings
Table 38. Novartis Macular Degeneration (AMD) and Other Retinal Diseases Revenue (US$, Mn), (2017-2022)
Table 39. Roche Corporate Summary
Table 40. Roche Macular Degeneration (AMD) and Other Retinal Diseases Product Offerings
Table 41. Roche Macular Degeneration (AMD) and Other Retinal Diseases Revenue (US$, Mn), (2017-2022)
Table 42. Kanghong Pharma Corporate Summary
Table 43. Kanghong Pharma Macular Degeneration (AMD) and Other Retinal Diseases Product Offerings
Table 44. Kanghong Pharma Macular Degeneration (AMD) and Other Retinal Diseases Revenue (US$, Mn), (2017-2022)
Table 45. Merck Corporate Summary
Table 46. Merck Macular Degeneration (AMD) and Other Retinal Diseases Product Offerings
Table 47. Merck Macular Degeneration (AMD) and Other Retinal Diseases Revenue (US$, Mn), (2017-2022)
Table 48. Allergan Corporate Summary
Table 49. Allergan Macular Degeneration (AMD) and Other Retinal Diseases Product Offerings
Table 50. Allergan Macular Degeneration (AMD) and Other Retinal Diseases Revenue (US$, Mn), (2017-2022)
Table 51. Santen Pharmaceutical Corporate Summary
Table 52. Santen Pharmaceutical Macular Degeneration (AMD) and Other Retinal Diseases Product Offerings
Table 53. Santen Pharmaceutical Macular Degeneration (AMD) and Other Retinal Diseases Revenue (US$, Mn), (2017-2022)
Table 54. GlaxoSmithKline Pharmaceuticals Corporate Summary
Table 55. GlaxoSmithKline Pharmaceuticals Macular Degeneration (AMD) and Other Retinal Diseases Product Offerings
Table 56. GlaxoSmithKline Pharmaceuticals Macular Degeneration (AMD) and Other Retinal Diseases Revenue (US$, Mn), (2017-2022)
Table 57. Pfizer Corporate Summary
Table 58. Pfizer Macular Degeneration (AMD) and Other Retinal Diseases Product Offerings
Table 59. Pfizer Macular Degeneration (AMD) and Other Retinal Diseases Revenue (US$, Mn), (2017-2022)
Table 60. Acucela Corporate Summary
Table 61. Acucela Macular Degeneration (AMD) and Other Retinal Diseases Product Offerings
Table 62. Acucela Macular Degeneration (AMD) and Other Retinal Diseases Revenue (US$, Mn), (2017-2022)
Table 63. Valent Pharmaceuticals Corporate Summary
Table 64. Valent Pharmaceuticals Macular Degeneration (AMD) and Other Retinal Diseases Product Offerings
Table 65. Valent Pharmaceuticals Macular Degeneration (AMD) and Other Retinal Diseases Revenue (US$, Mn), (2017-2022)
Table 66. IVERIC Corporate Summary
Table 67. IVERIC Macular Degeneration (AMD) and Other Retinal Diseases Product Offerings
Table 68. IVERIC Macular Degeneration (AMD) and Other Retinal Diseases Revenue (US$, Mn), (2017-2022)

List Of Figures

LIST OF FIGURES

Figure 1. Macular Degeneration (AMD) and Other Retinal Diseases Segment by Type in 2021
Figure 2. Macular Degeneration (AMD) and Other Retinal Diseases Segment by Application in 2021
Figure 3. Global Macular Degeneration (AMD) and Other Retinal Diseases Market Overview: 2021
Figure 4. Key Caveats
Figure 5. Global Macular Degeneration (AMD) and Other Retinal Diseases Market Size: 2021 VS 2028 (US$, Mn)
Figure 6. Global Macular Degeneration (AMD) and Other Retinal Diseases Revenue, 2017-2028 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Macular Degeneration (AMD) and Other Retinal Diseases Revenue in 2021
Figure 8. By Type - Global Macular Degeneration (AMD) and Other Retinal Diseases Revenue Market Share, 2017-2028
Figure 9. By Application - Global Macular Degeneration (AMD) and Other Retinal Diseases Revenue Market Share, 2017-2028
Figure 10. By Region - Global Macular Degeneration (AMD) and Other Retinal Diseases Revenue Market Share, 2017-2028
Figure 11. By Country - North America Macular Degeneration (AMD) and Other Retinal Diseases Revenue Market Share, 2017-2028
Figure 12. US Macular Degeneration (AMD) and Other Retinal Diseases Revenue, (US$, Mn), 2017-2028
Figure 13. Canada Macular Degeneration (AMD) and Other Retinal Diseases Revenue, (US$, Mn), 2017-2028
Figure 14. Mexico Macular Degeneration (AMD) and Other Retinal Diseases Revenue, (US$, Mn), 2017-2028
Figure 15. By Country - Europe Macular Degeneration (AMD) and Other Retinal Diseases Revenue Market Share, 2017-2028
Figure 16. Germany Macular Degeneration (AMD) and Other Retinal Diseases Revenue, (US$, Mn), 2017-2028
Figure 17. France Macular Degeneration (AMD) and Other Retinal Diseases Revenue, (US$, Mn), 2017-2028
Figure 18. U.K. Macular Degeneration (AMD) and Other Retinal Diseases Revenue, (US$, Mn), 2017-2028
Figure 19. Italy Macular Degeneration (AMD) and Other Retinal Diseases Revenue, (US$, Mn), 2017-2028
Figure 20. Russia Macular Degeneration (AMD) and Other Retinal Diseases Revenue, (US$, Mn), 2017-2028
Figure 21. Nordic Countries Macular Degeneration (AMD) and Other Retinal Diseases Revenue, (US$, Mn), 2017-2028
Figure 22. Benelux Macular Degeneration (AMD) and Other Retinal Diseases Revenue, (US$, Mn), 2017-2028
Figure 23. By Region - Asia Macular Degeneration (AMD) and Other Retinal Diseases Revenue Market Share, 2017-2028
Figure 24. China Macular Degeneration (AMD) and Other Retinal Diseases Revenue, (US$, Mn), 2017-2028
Figure 25. Japan Macular Degeneration (AMD) and Other Retinal Diseases Revenue, (US$, Mn), 2017-2028
Figure 26. South Korea Macular Degeneration (AMD) and Other Retinal Diseases Revenue, (US$, Mn), 2017-2028
Figure 27. Southeast Asia Macular Degeneration (AMD) and Other Retinal Diseases Revenue, (US$, Mn), 2017-2028
Figure 28. India Macular Degeneration (AMD) and Other Retinal Diseases Revenue, (US$, Mn), 2017-2028
Figure 29. By Country - South America Macular Degeneration (AMD) and Other Retinal Diseases Revenue Market Share, 2017-2028
Figure 30. Brazil Macular Degeneration (AMD) and Other Retinal Diseases Revenue, (US$, Mn), 2017-2028
Figure 31. Argentina Macular Degeneration (AMD) and Other Retinal Diseases Revenue, (US$, Mn), 2017-2028
Figure 32. By Country - Middle East & Africa Macular Degeneration (AMD) and Other Retinal Diseases Revenue Market Share, 2017-2028
Figure 33. Turkey Macular Degeneration (AMD) and Other Retinal Diseases Revenue, (US$, Mn), 2017-2028
Figure 34. Israel Macular Degeneration (AMD) and Other Retinal Diseases Revenue, (US$, Mn), 2017-2028
Figure 35. Saudi Arabia Macular Degeneration (AMD) and Other Retinal Diseases Revenue, (US$, Mn), 2017-2028
Figure 36. UAE Macular Degeneration (AMD) and Other Retinal Diseases Revenue, (US$, Mn), 2017-2028
Figure 37. Regeneron Pharmaceuticals Macular Degeneration (AMD) and Other Retinal Diseases Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 38. Bayer HealthCare Macular Degeneration (AMD) and Other Retinal Diseases Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 39. Novartis Macular Degeneration (AMD) and Other Retinal Diseases Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 40. Roche Macular Degeneration (AMD) and Other Retinal Diseases Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 41. Kanghong Pharma Macular Degeneration (AMD) and Other Retinal Diseases Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 42. Merck Macular Degeneration (AMD) and Other Retinal Diseases Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 43. Allergan Macular Degeneration (AMD) and Other Retinal Diseases Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 44. Santen Pharmaceutical Macular Degeneration (AMD) and Other Retinal Diseases Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 45. GlaxoSmithKline Pharmaceuticals Macular Degeneration (AMD) and Other Retinal Diseases Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 46. Pfizer Macular Degeneration (AMD) and Other Retinal Diseases Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 47. Acucela Macular Degeneration (AMD) and Other Retinal Diseases Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 48. Valent Pharmaceuticals Macular Degeneration (AMD) and Other Retinal Diseases Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 49. IVERIC Macular Degeneration (AMD) and Other Retinal Diseases Revenue Year Over Year Growth (US$, Mn) & (2017-2022)